AnaptysBio Inc Cash Flow Conversion Efficiency
AnaptysBio Inc cash flow conversion efficiency. Based on the latest financial reports, AnaptysBio Inc (ANAB) has a cash flow conversion efficiency ratio of -2.033x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.92 Million) by net assets ($12.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of AnaptysBio Inc (2013–2025)
Cash flow conversion efficiency of AnaptysBio Inc from 2013 to 2025. This chart illustrates how AnaptysBio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AnaptysBio Inc (ANAB) share price today for real-time trading data and today's change.
AnaptysBio Inc Cash Flow Conversion Ratio Explained
AnaptysBio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AnaptysBio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AnaptysBio Inc ranked by their cash flow conversion efficiency. Also see market cap of AnaptysBio Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gemdale Corp
SHG:600383
|
-0.002x |
|
Siam City Cement Public Company Limited
BK:SCCC
|
0.028x |
|
Distribution Solutions Group Inc
NASDAQ:DSGR
|
0.059x |
|
Television Francaise 1 SA
PA:TFI
|
0.057x |
|
Greattown Holdings Ltd A
SHG:600094
|
0.014x |
|
VIVENDI UNSPON.ARD EO 55
F:VVUD
|
N/A |
|
Lotte Chemical Corp
KO:011170
|
-0.034x |
|
Sitio Royalties Corp.
NYSE:STR
|
0.026x |
Annual Cash Flow Conversion Efficiency for AnaptysBio Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of AnaptysBio Inc from 2013 to 2025. Review AnaptysBio Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $37.21 Million | $19.70 Million | 0.529x | +127.72% |
| 2024-12-31 | $70.87 Million | $-135.34 Million | -1.910x | -39.28% |
| 2023-12-31 | $88.10 Million | $-120.80 Million | -1.371x | -388.33% |
| 2022-12-31 | $262.10 Million | $-73.59 Million | -0.281x | -117.94% |
| 2021-12-31 | $356.43 Million | $-45.92 Million | -0.129x | -261.04% |
| 2020-12-31 | $396.73 Million | $-14.16 Million | -0.036x | +79.21% |
| 2019-12-31 | $405.01 Million | $-69.52 Million | -0.172x | -72.11% |
| 2018-12-31 | $486.37 Million | $-48.51 Million | -0.100x | -57.81% |
| 2017-12-31 | $307.58 Million | $-19.44 Million | -0.063x | +72.52% |
| 2016-12-31 | $39.27 Million | $-9.03 Million | -0.230x | -0.69% |
| 2015-12-31 | $42.34 Million | $-9.67 Million | -0.228x | -109.37% |
| 2014-12-31 | $5.99 Million | $14.60 Million | 2.437x | +106.10% |
| 2013-12-31 | $145.00K | $-5.80 Million | -39.972x | -- |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial… Read more